KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsR&D In ProcessReceivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Eli Lilly (LLY) Accumulated Depreciation & Amortization (2016 - 2025)

Eli Lilly's Accumulated Depreciation & Amortization history spans 17 years, with the latest figure at $2.0 billion for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 13.02% year-over-year to $2.0 billion; the TTM value through Dec 2025 reached $2.0 billion, up 13.02%, while the annual FY2025 figure was $2.0 billion, 13.02% up from the prior year.
  • Accumulated Depreciation & Amortization reached $2.0 billion in Q4 2025 per LLY's latest filing, up from $470.0 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $2.0 billion in Q4 2025 to a low of $350.3 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $891.2 million, with a median of $724.1 million recorded in 2021.
  • Peak YoY movement for Accumulated Depreciation & Amortization: increased 28.03% in 2021, then plummeted 59.04% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $1.5 billion in 2021, then fell by 1.62% to $1.5 billion in 2022, then increased by 0.3% to $1.5 billion in 2023, then rose by 15.72% to $1.8 billion in 2024, then increased by 13.02% to $2.0 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Accumulated Depreciation & Amortization are $2.0 billion (Q4 2025), $470.0 million (Q3 2025), and $478.5 million (Q2 2025).